Corticosteroids and infliximab impair the performance of interferon-γrelease assays used for diagnosis of latent tuberculosis

43Citations
Citations of this article
44Readers
Mendeley users who have this article in their library.

Abstract

The impact of immunosuppression on interferon-γrelease assays and novel cytokine biomarkers of TB infection, mycobacteria-specific IL-2, IP-10 and TNF-α responses was investigated in an ex vivo model. Cytokine responses in standard QuantiFERON-TB Gold in-Tube (QFT-GIT) assays were compared with duplicate assays containing dexamethasone or infliximab. Dexamethasone converted QFT-GIT results from positive to negative in 30% of participants. Antigen-stimulated interferon-γ, IL-2 and TNF-α responses were markedly reduced, but IP-10 responses were preserved. Infliximab caused QFT-GIT result conversion in up to 30% of participants and substantial reductions in all cytokine responses. Therefore, corticosteroids and anti-TNF-α agents significantly impair interferon-γrelease assay performance. IP-10 may be a more robust TB biomarker than interferon-γin patients receiving corticosteroids.

Author supplied keywords

Cite

CITATION STYLE

APA

Edwards, A., Gao, Y., Allan, R. N., Ball, D., De Graaf, H., Coelho, T., … Tebruegge, M. (2017). Corticosteroids and infliximab impair the performance of interferon-γrelease assays used for diagnosis of latent tuberculosis. Thorax, 72(10), 946–949. https://doi.org/10.1136/thoraxjnl-2016-209397

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free